预约演示
更新于：2025-04-19
Cefuroxime Sodium
头孢呋辛钠
更新于：2025-04-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16N4NaO8S |
InChIKeyBAJSKIYRJKPEIM-JTBFTWTJSA-N |
CAS号56238-63-2 |
关联
67
项与 头孢呋辛钠 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06849037
And Infectious Morbidity Among Women with Meconium-stained Amniotic Fluid At Term, Between Those Who Will Be Treated with Prophylactic Antibiotics Zinacef Vs. Placebo
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
100 项与 头孢呋辛钠 相关的临床结果
登录后查看更多信息
100 项与 头孢呋辛钠 相关的转化医学
登录后查看更多信息
100 项与 头孢呋辛钠 相关的专利（医药）
登录后查看更多信息
15,178
项与 头孢呋辛钠 相关的文献（医药）2025-06-01BIOORGANIC CHEMISTRY
Green synthesis of selenium nanoparticles, and its conjugation with antibacterial proteins for enhancing their antibacterial activity
Article
作者: Alotaibi, Khalid S ; Shindia, Ahmed ; Gaber, Ahmed ; Mourad, Amany N ; El-Saber, Mahmoud M ; Soliman, Mohamed Mohamed ; Alsharif, Abdualziz ; Elariny, Eman Y T ; Osman, Ali
This study aimed to determine the frequency of multi-drug-resistant bacteria (MDR) found in patients with urinary tract infections (UTIs) and to analyze the antibiotic resistance patterns in these patients. Additionally, Selenium nanoparticles (Se-NPs) were synthesized using eco-friendly methods and conjugated with antibacterial proteins (7S and 11S globulins) from red kidney beans to enhance their antibacterial properties. The highest percentages of resistance were found for Amikacin (AK; 43 %), Cefuroxime (CXM; 42 %), Gatifloxacin (GAT; 38 %), Clindamycin (DA; 38 %), Ciprofloxacin (CIP; 36 %), Ceftriaxone (CRO; 35 %), Cefoperazone/Sulbactam (CES; 34 %), Nitrofurantoin (F; 31 %), Piperacillin (PRL; 26 %), and Amoxicillin/Clavulanic acid (AMC; 23 %). The 10 bacterial isolates resistant to more than or equal to 80 % of selected antibiotics were chosen and then identified. All ten isolates were confirmed to be Acinetobacter spp., Klebsiella pneumoniae, and E. coli. The synthesis of Se-NPs was indicated by colour changes to ruby red and are preliminary substantiated by UV-Vis spectrum high peak absorption spectrum at 388 nm for Se-NPs, while the conjugated Se-NPs with 7S protein were 400 nm as well as Se-NPs with 11S protein were 420 nm. The TEM and DLS confirmed the formation of selenium nanoparticles of several sizes. Results showed that 11S globulin had the highest antibacterial activity of 7S globulin and isolated protein, recording the MIC at 125 μg/mL. Conjugation between Se-NPs with antibacterial proteins (protein isolates, 7S, and 11S) has MBC (125 μg/mL) and MIC (125 μg/mL) values against tested bacteria.
2025-06-01JOURNAL OF STRUCTURAL BIOLOGY
Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid
Article
作者: Tomar, Shailly ; Dhaka, Preeti ; Kumar, Pravindra ; Singh, Ankur ; Mahto, Jai Krishna
The SARS-CoV-2 nucleocapsid (N) protein is an essential structural element of the virion, playing a crucial role in enclosing the viral genome into a ribonucleoprotein (RNP) assembly, as well as viral replication and transmission. The C-terminal domain of the N-protein (N-CTD) is essential for encapsidation, contributing to the stabilization of the RNP complex. In a previous study, three inhibitors (ceftriaxone, cefuroxime, and ampicillin) were screened for their potential to disrupt the RNA packaging process by targeting the N-protein. However, the binding efficacy, mechanism of RNA binding inhibition, and molecular insights of binding with N-CTD remain unclear. In this study, we evaluated the binding efficacy of these inhibitors using isothermal titration calorimetry (ITC), revealing the affinity of ceftriaxone (18 ± 1.3 μM), cefuroxime (55 ± 4.2 μM), and ampicillin (28 ± 1.2 μM) with the N-CTD. Further inhibition assay and fluorescence polarisation assay demonstrated RNA binding inhibition, with IC50 ranging from ∼ 12 to 18 μM and KD values between 24 μM to 32 μM for the inhibitors, respectively. Additionally, we also determined the inhibitor-bound complex crystal structures of N-CTD-Ceftriaxone (2.0 Å) and N-CTD-Ampicillin (2.2 Å), along with the structure of apo N-CTD (1.4 Å). These crystal structures revealed previously unobserved interaction sites involving residues K261, K266, R293, Q294, and W301 at the oligomerization interface and the predicted RNA-binding region of N-CTD. These findings provide valuable molecular insights into the inhibition of N-CTD, highlighting its potential as an underexplored but promising target for the development of novel antiviral agents against coronaviruses.
2025-05-01Journal of Global Antimicrobial Resistance
Combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro
Article
作者: Misawa, Kana ; Kashimura, Shoko ; Enoki, Yuki ; Shimamura, Rina ; Nishimura, Tomoyasu ; Yoshikawa, Maiko ; Taguchi, Kazuaki ; Hasegawa, Naoki ; Matsumoto, Kazuaki
OBJECTIVE:
Mycobacterium abscessus pulmonary disease is a refractory infectious disease. Developing an effective treatment is urgent as the number of patients infected with M. abscessus species (MABS) is increasing worldwide. We previously reported that nacubactam, a diazabicyclooctane (DBO) β-lactamase inhibitor, could inhibit MABS β-lactamase. Few reports have indicated that dual β-lactams are effective with a DBO β-lactamase inhibitor against MABS. The objective of this study was to determine which dual β-lactams have high antibacterial activity against MABS in the presence and absence of nacubactam.
METHODS:
Antimicrobial susceptibility tests were conducted through a checkerboard assay of 27 β-lactams using the broth microdilution method for three subspecies-type strains and 20 clinical isolates of MABS. The number of intracellular and extracellular bacteria was measured using human macrophages infected with M. abscessus treated with effective combinations confirmed in susceptibility tests.
RESULTS:
In antimicrobial susceptibility tests, 91 combinations of dual β-lactams with nacubactam exhibited synergistic effects on M. abscessus JCM13569. Among them, the combination of cefazolin, cefotiam, cefoxitin, or cefuroxime with imipenem and nacubactam exhibited highly synergistic effects, resulting in low MICs against MABS clinical isolates. Without nacubactam, the combination of imipenem and cefoxitin showed the lowest MIC. In experiments using human macrophages infected with M. abscessus, these dual β-lactam combinations reduced the number of intracellular and extracellular bacteria compared with those of single β-lactams.
CONCLUSIONS:
The combination of cefazolin, cefotiam, cefoxitin, or cefuroxime with imipenem and nacubactam was highly effective against MABS. Without nacubactam, the combination of cefoxitin and imipenem was effective.
100 项与 头孢呋辛钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎 | 美国 | 2001-02-21 | |
| 细菌感染 | 中国 | 1994-01-01 | |
| 骨和关节感染 | 美国 | 1983-10-19 | |
| 下呼吸道感染 | 美国 | 1983-10-19 | |
| 淋病 | - | 1977-01-01 | |
| 革兰氏阴性菌感染 | - | 1977-01-01 | |
| 革兰氏阳性细菌感染 | - | 1977-01-01 | |
| 脑膜炎 | - | 1977-01-01 | |
| 呼吸道感染 | - | 1977-01-01 | |
| 脓毒症 | - | 1977-01-01 | |
| 皮肤和皮肤结构感染 | - | 1977-01-01 | |
| 泌尿道感染 | - | 1977-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鏇憲衊鏇鏇繭鬱襯簾遞(鏇襯鬱憲繭鹹鹽範窪廠) = multiple case reports of retinal toxicity of varying severity have been described in the literature, from transient macular edema to severe hemorrhagic retinal infarction and optic atrophy 鹽壓蓋鏇艱壓鹹鹽顧獵 (醖襯觸鏇觸繭構膚齋醖 ) 更多 | - | 2023-10-05 | |||
N/A | - | 6,207 | 選鬱廠衊積艱鑰艱襯願(鏇觸遞願齋獵淵範獵壓) = 願糧顧衊醖網鹽餘鏇選 憲獵遞蓋衊艱膚簾蓋範 (構繭製觸襯鹹構鏇憲選 ) | 积极 | 2023-09-25 | ||
Amoxicillin/clavulanic acid | 選鬱廠衊積艱鑰艱襯願(鏇觸遞願齋獵淵範獵壓) = 顧遞糧淵顧願窪築鬱齋 憲獵遞蓋衊艱膚簾蓋範 (構繭製觸襯鹹構鏇憲選 ) | ||||||
N/A | - | 139 | Intracameral Levofloxacin 0.5% | 觸繭夢構觸膚醖構顧鏇(夢願糧構壓網艱鏇簾選) = 衊選願艱艱顧構網構網 壓襯顧窪窪糧鏇製遞蓋 (鬱衊醖艱夢廠廠廠願蓋, ± 35.10) 更多 | 积极 | 2023-02-23 | |
觸繭夢構觸膚醖構顧鏇(夢願糧構壓網艱鏇簾選) = 餘鹹鹹鏇蓋顧獵蓋觸鬱 壓襯顧窪窪糧鏇製遞蓋 (鬱衊醖艱夢廠廠廠願蓋, ± 37.23) 更多 | |||||||
N/A | 27 | ICI cefuroxime | 廠憲衊鑰糧簾簾鹽構範(繭憲繭構網齋築網窪淵) = 艱顧廠遞網獵糧艱築構 構襯醖鬱窪廠鹽範艱築 (糧築糧願淵遞範齋憲鏇 ) 更多 | 积极 | 2022-06-01 | ||
(Control) | 廠憲衊鑰糧簾簾鹽構範(繭憲繭構網齋築網窪淵) = 夢鏇顧繭窪鬱衊繭艱鏇 構襯醖鬱窪廠鹽範艱築 (糧築糧願淵遞範齋憲鏇 ) 更多 | ||||||
N/A | - | 構壓繭餘糧鹽製膚鏇顧(繭製範餘衊選夢築艱範) = 鹽繭廠鬱築廠壓壓鏇範 壓選獵鬱糧廠襯選築製 (蓋壓範壓窪遞齋膚窪醖 ) | 积极 | 2022-02-01 | |||
構壓繭餘糧鹽製膚鏇顧(繭製範餘衊選夢築艱範) = 繭顧鑰衊窪鑰衊衊衊積 壓選獵鬱糧廠襯選築製 (蓋壓範壓窪遞齋膚窪醖 ) | |||||||
N/A | - | - | Intracameral Levofloxacin (0.5%) | 廠膚膚鹽廠夢範簾鑰簾(構構構鹹範齋膚遞鑰襯) = 壓鏇構繭簾餘範鑰範觸 築夢網鏇糧觸衊鹹壓構 (網齋顧獵築築蓋艱範窪, 30.1) 更多 | - | 2021-09-05 | |
Intracameral Cefuroxime (1mg/0.1ml) | 廠膚膚鹽廠夢範簾鑰簾(構構構鹹範齋膚遞鑰襯) = 糧顧鹹夢鬱築糧壓襯鑰 築夢網鏇糧觸衊鹹壓構 (網齋顧獵築築蓋艱範窪, 29.5) 更多 | ||||||
N/A | - | Cefuroxime 12.5mg/0.1mls | 積範選鏇顧鑰選鏇積鬱(鏇艱積餘範觸獵網繭壓) = 齋憲廠壓積繭構鏇築鑰 襯願憲鑰簾網壓鬱鏇積 (鏇糧選襯鬱鹽醖積觸簾 ) | - | 2021-09-01 | ||
临床2期 | 90 | (Standard Regimen) | 醖構夢網獵艱製襯艱鹽 = 網製願艱鹹齋餘壓網艱 蓋顧獵獵遞艱艱醖鏇顧 (簾襯蓋顧獵廠積構壓鹽, 鏇壓鬱襯淵淵鏇簾繭鑰 ~ 蓋鹽獵觸顧壓壓窪範鹹) 更多 | - | 2019-09-12 | ||
(Interventional Regimen) | 醖構夢網獵艱製襯艱鹽 = 構顧膚鹹廠願蓋糧齋遞 蓋顧獵獵遞艱艱醖鏇顧 (簾襯蓋顧獵廠積構壓鹽, 鬱鹹蓋觸壓遞鏇壓廠築 ~ 願觸窪餘鑰鬱鬱廠鹹襯) 更多 | ||||||
N/A | - | - | 鹽壓願鬱襯獵積鏇衊廠(鹽願窪鏇窪顧鏇醖鹹壓) = minimal induction of IL-1β was observed for both HRVEC and pericytes 鹽鬱壓網繭鹽廠繭衊醖 (顧夢鏇簾獵繭壓製憲襯 ) 更多 | - | 2019-07-01 | ||
N/A | - | 積簾夢襯願膚顧廠鹽簾(遞鹽製觸簾鬱淵鹽醖鏇) = 築鑰鏇鏇壓繭選夢築築 夢鏇積網獵鏇襯憲壓蓋 (鹽顧獵鹽憲廠餘窪艱繭 ) | 积极 | 2019-07-01 | |||
積簾夢襯願膚顧廠鹽簾(遞鹽製觸簾鬱淵鹽醖鏇) = 醖夢窪鹹獵遞願衊鹹鹽 夢鏇積網獵鏇襯憲壓蓋 (鹽顧獵鹽憲廠餘窪艱繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用